Strides Arcolab January-March net profit zooms to Rs 642 crore
The Bangalore-headquartered firm had sold its entire stake in Australian subsidiary Ascent Pharmahealth to Watson Pharmaceuticals.
By PTI | Updated:
NEW DELHI: Drug firm Strides Arcolab today reported a consolidated net profit of Rs 642.18 crore for the quarter ended March 31, 2012, primarily on the back of its entire stake sale in Australian arm ' Ascent Pharmahealth'.
The Bangalore-headquartered firm had sold its entire stake in Australian subsidiary Ascent Pharmahealth to Watson Pharmaceuticals for AUD 375 million in January this year.
The company had posted a net profit of Rs 45.08 crore in the same period last year, Strides Arcolab said in a statement.
Net sales of the company stood at Rs 527.47 crore for the first quarter ended March 31, 2012, as against Rs 487.47 crore in the same period previous year.
Commenting on the results Strides Arcolab Ltd Vice- Chairman and Group CEO Arun Kumar said: "The quarter's strong operational performance in both Specialties and Pharma businesses reflect the company's strongly articulated niche IP led strategy."
"Agila's performance is driven by significant operating leverage and ramp up in capacity utilisation with continued regulatory approval momentum," he added.
Agila, which is the specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars.
On a standalone basis, the company posted a net loss of Rs 28.15 crore for the first quarter. It had posted a net profit of Rs 12.74 crore in the same period last year.
Shares of Strides Arcolab were trading at Rs 650.50 on the BSE in the late afternoon trade, down 1.48 per cent from its previous close.
The Bangalore-headquartered firm had sold its entire stake in Australian subsidiary Ascent Pharmahealth to Watson Pharmaceuticals for AUD 375 million in January this year.
The company had posted a net profit of Rs 45.08 crore in the same period last year, Strides Arcolab said in a statement.
Net sales of the company stood at Rs 527.47 crore for the first quarter ended March 31, 2012, as against Rs 487.47 crore in the same period previous year.
Commenting on the results Strides Arcolab Ltd Vice- Chairman and Group CEO Arun Kumar said: "The quarter's strong operational performance in both Specialties and Pharma businesses reflect the company's strongly articulated niche IP led strategy."
"Agila's performance is driven by significant operating leverage and ramp up in capacity utilisation with continued regulatory approval momentum," he added.
ADVERTISEMENT
Agila, which is the specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars.
On a standalone basis, the company posted a net loss of Rs 28.15 crore for the first quarter. It had posted a net profit of Rs 12.74 crore in the same period last year.
Shares of Strides Arcolab were trading at Rs 650.50 on the BSE in the late afternoon trade, down 1.48 per cent from its previous close.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
